| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 6589053
[patent_doc_number] => 20100291601
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-11-18
[patent_title] => 'CARBOHYDRATE BINDING MODULE AND USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 12/755242
[patent_app_country] => US
[patent_app_date] => 2010-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 4149
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0291/20100291601.pdf
[firstpage_image] =>[orig_patent_app_number] => 12755242
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/755242 | Method for the detection of human immunodeficiency virus envelope (HIV) glycoprotein utilizing carbohydrate binding module (CBM) 20 or 21 | Apr 5, 2010 | Issued |
Array
(
[id] => 11793225
[patent_doc_number] => 09402917
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-08-02
[patent_title] => 'Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions'
[patent_app_type] => utility
[patent_app_number] => 13/262706
[patent_app_country] => US
[patent_app_date] => 2010-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 26
[patent_no_of_words] => 8582
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13262706
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/262706 | Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions | Apr 4, 2010 | Issued |
Array
(
[id] => 9823712
[patent_doc_number] => 08933198
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-01-13
[patent_title] => 'HIV VPR-specific T cell receptors'
[patent_app_type] => utility
[patent_app_number] => 12/731485
[patent_app_country] => US
[patent_app_date] => 2010-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 34
[patent_no_of_words] => 9545
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12731485
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/731485 | HIV VPR-specific T cell receptors | Mar 24, 2010 | Issued |
Array
(
[id] => 6271309
[patent_doc_number] => 20100255078
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-10-07
[patent_title] => 'SERPIN DRUGS FOR TREATMENT OF VIRAL INFECTION AND METHOD OF USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 12/727853
[patent_app_country] => US
[patent_app_date] => 2010-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 19309
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0255/20100255078.pdf
[firstpage_image] =>[orig_patent_app_number] => 12727853
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/727853 | Method of treating human immunodeficiency virus infection in a mammal comprising administering heparin-activated antithrombin III | Mar 18, 2010 | Issued |
Array
(
[id] => 6070144
[patent_doc_number] => 20110044994
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-02-24
[patent_title] => 'HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 12/726245
[patent_app_country] => US
[patent_app_date] => 2010-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 55220
[patent_no_of_claims] => 42
[patent_no_of_ind_claims] => 23
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0044/20110044994.pdf
[firstpage_image] =>[orig_patent_app_number] => 12726245
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/726245 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Mar 16, 2010 | Issued |
Array
(
[id] => 6234931
[patent_doc_number] => 20100266635
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-10-21
[patent_title] => 'HIVCON: AN HIV IMMUNOGEN AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 12/725651
[patent_app_country] => US
[patent_app_date] => 2010-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 35688
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0266/20100266635.pdf
[firstpage_image] =>[orig_patent_app_number] => 12725651
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/725651 | Peptide library obtained from multi-clade chimeric immunogens derived from highly conserved regions of the human immunodeficiency virus type 1 (HIV-1) consensus proteome | Mar 16, 2010 | Issued |
Array
(
[id] => 6379483
[patent_doc_number] => 20100316570
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-12-16
[patent_title] => 'Protection of Virus from Immune Cell Uptake'
[patent_app_type] => utility
[patent_app_number] => 12/721287
[patent_app_country] => US
[patent_app_date] => 2010-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 21770
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0316/20100316570.pdf
[firstpage_image] =>[orig_patent_app_number] => 12721287
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/721287 | Protection of virus particles from phagocytosis by expression of CD47 | Mar 9, 2010 | Issued |
Array
(
[id] => 8113829
[patent_doc_number] => 08158130
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-04-17
[patent_title] => 'Method for the preparation of virus-like particles (VLPS) comprising heterologous multiple membrane spanning proteins'
[patent_app_type] => utility
[patent_app_number] => 12/720398
[patent_app_country] => US
[patent_app_date] => 2010-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 16
[patent_no_of_words] => 33155
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/158/08158130.pdf
[firstpage_image] =>[orig_patent_app_number] => 12720398
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/720398 | Method for the preparation of virus-like particles (VLPS) comprising heterologous multiple membrane spanning proteins | Mar 8, 2010 | Issued |
Array
(
[id] => 9354776
[patent_doc_number] => 08673307
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2014-03-18
[patent_title] => 'HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120'
[patent_app_type] => utility
[patent_app_number] => 12/719356
[patent_app_country] => US
[patent_app_date] => 2010-03-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 52
[patent_figures_cnt] => 41
[patent_no_of_words] => 12364
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12719356
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/719356 | HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120 | Mar 7, 2010 | Issued |
Array
(
[id] => 6500614
[patent_doc_number] => 20100215682
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-08-26
[patent_title] => 'DELETION OF THE BETA 20-21 LOOP IN HIV GP120 EXPOSES THE CD4 BINDING SITE FOR IMPROVED ANTIBODY BINDING AND ANTIBODY INDUCTION'
[patent_app_type] => utility
[patent_app_number] => 12/714085
[patent_app_country] => US
[patent_app_date] => 2010-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 30163
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0215/20100215682.pdf
[firstpage_image] =>[orig_patent_app_number] => 12714085
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/714085 | Deletion of the beta 20-21 loop in HIV gp120 exposes the CD4 binding site for improved antibody binding and antibody induction | Feb 25, 2010 | Issued |
Array
(
[id] => 6395529
[patent_doc_number] => 20100178302
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-07-15
[patent_title] => 'CHRONIC PATHOGEN-EXPRESSING CELL LINES'
[patent_app_type] => utility
[patent_app_number] => 12/705032
[patent_app_country] => US
[patent_app_date] => 2010-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 6023
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0178/20100178302.pdf
[firstpage_image] =>[orig_patent_app_number] => 12705032
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/705032 | CHRONIC PATHOGEN-EXPRESSING CELL LINES | Feb 11, 2010 | Abandoned |
Array
(
[id] => 10077343
[patent_doc_number] => 09115186
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-08-25
[patent_title] => 'Stabilized trimeric HIV-1 gp41 fusion polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif'
[patent_app_type] => utility
[patent_app_number] => 12/702209
[patent_app_country] => US
[patent_app_date] => 2010-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 15
[patent_no_of_words] => 9366
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12702209
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/702209 | Stabilized trimeric HIV-1 gp41 fusion polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif | Feb 7, 2010 | Issued |
Array
(
[id] => 6228931
[patent_doc_number] => 20100183669
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-07-22
[patent_title] => 'Mannose immunogens for HIV-1'
[patent_app_type] => utility
[patent_app_number] => 12/656550
[patent_app_country] => US
[patent_app_date] => 2010-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 6105
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0183/20100183669.pdf
[firstpage_image] =>[orig_patent_app_number] => 12656550
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/656550 | Mannose immunogens for HIV-1 | Feb 2, 2010 | Abandoned |
Array
(
[id] => 7766878
[patent_doc_number] => 20120034597
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-02-09
[patent_title] => 'METHODS OF MONITORING TREATMENT OF AVIREMIC HIV-INFECTED PATIENTS'
[patent_app_type] => utility
[patent_app_number] => 13/145307
[patent_app_country] => US
[patent_app_date] => 2010-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 7107
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0034/20120034597.pdf
[firstpage_image] =>[orig_patent_app_number] => 13145307
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/145307 | Methods of monitoring treatment effectiveness in HIV-infected patients receiveing intensified HAART regimens by measuring episomal 2-LTR circles | Jan 28, 2010 | Issued |
Array
(
[id] => 8435158
[patent_doc_number] => 08282926
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-10-09
[patent_title] => 'CCR5-specific antibodies with HIV neutralizing activity that recognize a linear dodecapeptide that mimics a conformational epitope in the second extracellular loop of CCR5'
[patent_app_type] => utility
[patent_app_number] => 12/647789
[patent_app_country] => US
[patent_app_date] => 2009-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 26
[patent_no_of_words] => 19857
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12647789
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/647789 | CCR5-specific antibodies with HIV neutralizing activity that recognize a linear dodecapeptide that mimics a conformational epitope in the second extracellular loop of CCR5 | Dec 27, 2009 | Issued |
Array
(
[id] => 6430326
[patent_doc_number] => 20100143305
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-06-10
[patent_title] => 'TREATMENT OF HIV AND AIDS USING PROBIOTIC LACTOBACILLUS REUTERI'
[patent_app_type] => utility
[patent_app_number] => 12/633642
[patent_app_country] => US
[patent_app_date] => 2009-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 9451
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0143/20100143305.pdf
[firstpage_image] =>[orig_patent_app_number] => 12633642
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/633642 | TREATMENT OF HIV AND AIDS USING PROBIOTIC LACTOBACILLUS REUTERI | Dec 7, 2009 | Abandoned |
Array
(
[id] => 7710325
[patent_doc_number] => 20120003266
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-05
[patent_title] => 'VIRUS LIKE PARTICLE COMPOSITIONS AND METHODS OF USE'
[patent_app_type] => utility
[patent_app_number] => 13/131287
[patent_app_country] => US
[patent_app_date] => 2009-11-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 118
[patent_figures_cnt] => 118
[patent_no_of_words] => 22814
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13131287
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/131287 | Virus-like particles (VLPs) prepared from chikungunya virus structural proteins | Nov 23, 2009 | Issued |
Array
(
[id] => 6380750
[patent_doc_number] => 20100316698
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-12-16
[patent_title] => 'POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 12/620511
[patent_app_country] => US
[patent_app_date] => 2009-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 114
[patent_figures_cnt] => 114
[patent_no_of_words] => 40806
[patent_no_of_claims] => 67
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0316/20100316698.pdf
[firstpage_image] =>[orig_patent_app_number] => 12620511
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/620511 | POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF | Nov 16, 2009 | Abandoned |
Array
(
[id] => 9523602
[patent_doc_number] => 08747862
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-06-10
[patent_title] => 'Pathogenic west african human immunodeficiency virus type 2 (HIV-2) group F isolate'
[patent_app_type] => utility
[patent_app_number] => 13/129282
[patent_app_country] => US
[patent_app_date] => 2009-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 9327
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13129282
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/129282 | Pathogenic west african human immunodeficiency virus type 2 (HIV-2) group F isolate | Nov 12, 2009 | Issued |
Array
(
[id] => 6245586
[patent_doc_number] => 20100135989
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-06-03
[patent_title] => 'ANTI-HIV AGENTS'
[patent_app_type] => utility
[patent_app_number] => 12/618098
[patent_app_country] => US
[patent_app_date] => 2009-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 11864
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0135/20100135989.pdf
[firstpage_image] =>[orig_patent_app_number] => 12618098
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/618098 | ANTI-HIV AGENTS | Nov 12, 2009 | Abandoned |